Callyope vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Callyope (Paris, AWS Pioneers 2026) raised .41M seed with 8 clinical trials ongoing, using speech AI to detect psychiatric deterioration early and deliver objective data between visits.
About
Callyope is a Paris-based clinical AI company founded to improve outcomes in mental health through passive, continuous monitoring. The company applies speech analysis and machine learning to detect early signals of psychiatric deterioration, enabling clinicians to intervene before crises occur. Its core technology processes vocal biomarkers to track mood, cognition, and behavioral patterns over time without requiring patients to self-report symptoms.\n\nCallyope's platform is designed for integration within clinical workflows, targeting psychiatrists, mental health hospitals, and digital health providers. The product supports remote patient monitoring between visits, generating objective data streams that augment clinician judgment. Unlike consumer wellness apps, Callyope operates within regulated clinical environments and is built to meet the evidentiary standards required for reimbursement and adoption in European and US health systems.\n\nThe company raised a $2.41 million seed round to fund product development and clinical validation. It currently has eight clinical trials ongoing and was selected for the AWS Healthcare Accelerator Pioneers 2026 cohort, reflecting recognition of its technical and scientific rigor. Callyope's pipeline of trial data positions it to pursue regulatory clearance and reimbursement pathways, which would unlock hospital procurement and enterprise mental health contracts at scale.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.